













































Pharmaceuticals – Pipeline Overview¹ (as of Nov 6, 2023)

Phase 0 ²	Phase I	Phase II	Phase III
PSMA SMOL TAC (BAY 3563254)  ●	AhR Inhibitor (BAY 2416964)  ●	Regorafenib (combi Nivolumab) (BAY 734506)  ○	Darolutamide (AR Inhibitor)  ○
VVD STAT3 Inh (BAY 3630914)  ●	mEGFR Inhibitor (BAY 2927088)  ●	Asundexian (FXIa Inhibitor) (BAY 2433334)  ●	Finerenone (MR Antagonist)  ○
Next Generation Liver MRI (BAY 3393081)  ●	DGKzeta Inhibitor (BAY 2965501)  ●	Zabedoseritib (IRAK4 Inh.) (BAY 1834845)  ●	Vericiguat (sGC Stimulator)  ○
	CCR8 Ab (BAY 3375968)  ●	Runcaciguat (sGC Activator) (BAY 1101042)  ●	Asundexian (FXIa Inhibitor)  ●
	VVD KEAP1 Act (VVD-13307 aka NRF2 Inh, BAY 3605349)  ●		Elinzanetant (Neurokinin-1,3 Rec Antagonist)  ●
	DGKalpha Inh (BAY 2862789)  ●		Aflibercept 8mg (VEGF Inhibitor)  ○
	PSMA TAC (BAY 3546828)  ●		Gadoquatrane (High Relaxivity Contrast Agent)  ●
	Congestive Heart Failure rAAV Gene Therapy (AB-1002 aka NAN-101)  ●		
	sGC Activator Oral (BAY 3283142)  ●		
	Anti-a2AP (BAY 3018250)  ●		
	SEMA 3a (BAY 3401016)  ●		
	Anti-coagulant (BAY 3389934)  ●		
	Bemdaneprocel (Parkinson's Disease Cell Therapy) (BRT-DA01)  ●		
	Parkinson's Disease rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-PD)  ●		
	Multiple System Atrophy rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-MSA)  ●		
	Pompe Disease rAAV Gene Therapy (ACTUS-101)  ●		
	Huntington's Disease rAAV Gene Therapy (AB-1001 aka BV-101)  ●		
	LGMD2I/R9 rAAV Gene Therapy (AB-1003 aka LION-101)  ●		
	GPR84 Antagonist (BAY 3178275)  ●		
	BAY 2701250  ●		

 Oncology
 Cardiovascular+⁴
 Neurology & Rare Diseases
 Immunology
 Others
 New molecular entity
 Life cycle management

Submissions

Aflibercept 8mg (VEGF-Inhibitor)  ○

EU, JP: Diabetic Macular Edema (DME)
 # EU, JP, CN: Neovasc. Age-rel. Macular Degen. (nAMD)

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit
² Pre-clinical selected assets on path to IND ³ Conducted by Merck & Co ⁴ Including Precision Cardiovascular, Nephrology & Acute Care
 1 // Bayer Pharmaceuticals // Pipeline Overview November 6, 2023

